No Data
No Data
No Data
No Data
No Data
Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder
Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (
GlobeNewswireOct 19, 2022 04:11
Testosterone Drug Maker Clarus Files For Bankruptcy -- Market Talk
1534 ET - Publicly traded Clarus Therapeutics Holdings, the maker of testosterone drug Jatenzo, has filed for chapter 11 bankruptcy, saying it has missed its sales targets and been unable to meet its
Dow JonesSep 7, 2022 03:35
Clarus Files for Chapter 11 Bankruptcy, Eyes Auction of Testosterone Therapy Jatenzo
Clarus Therapeutics (OTCPK:CRXT) filed voluntary petitions under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware and want to pursue an auction and sale of its only commercial asse
Seeking AlphaSep 6, 2022 16:31
Clarus Therapeutics: Jatenzo Auction Projected to End in Late October >CRXT
Clarus Therapeutics: Jatenzo Auction Projected to End in Late October >CRXT
Dow JonesSep 6, 2022 10:26
Clarus Therapeutics Seeks Authorization to Pursue Auction, Sale Process for Sole Commercial Asset Jatenzo >CRXT
Clarus Therapeutics Seeks Authorization to Pursue Auction, Sale Process for Sole Commercial Asset Jatenzo >CRXT
Dow JonesSep 6, 2022 10:26
Clarus Therapeutics Files Voluntary Petitions Under Chapter 11 >CRXT
Clarus Therapeutics Files Voluntary Petitions Under Chapter 11 >CRXT
Dow JonesSep 6, 2022 10:25
No Data
No Data